Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DC-CIK + NK cells
- Development stage
- Unknown
- Lead developer
- Ever Supreme Bio-Technology
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
DC-CIK + NK cells is a combination cellular immunotherapy composed of dendritic cells (DC), cytokine-induced killer (CIK) cells, and natural killer (NK) cells. Dendritic cells are potent antigen-presenting immune cells that can prime T lymphocytes, while CIKs are a heterogeneous population of ex vivo expanded T lymphocytes with both T-cell and NK-cell properties, capable of non-MHC-restricted tumor killing. The addition of autologous or allogeneic NK cells further enhances the cytotoxic response against tumor targets. This combination aims to synergistically boost anti-tumor immunity by leveraging the antigen presentation capacity of DCs, the broad cytotoxicity of CIKs, and the innate immune activity of NK cells. It has been investigated primarily for use in various solid tumors and hematological malignancies as an adjunct to standard therapies such as chemotherapy or radiotherapy[1][2][3][5].
- Other names
- dendritic cell-cytokine-induced killer cells plus natural killer cellsDC-CIK and NK cell therapy
02
Targets
NCR3LG1 (Natural cytotoxicity triggering receptor 3 ligand 1)pMHC (Peptide-MHC complex family)NECTIN1 (Poliovirus receptor-related 1)MICB (Major histocompatibility complex class i-related protein B)
Beyond the preview
Go deeper on DC-CIK + NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DC-CIK + NK cells.